Sort by
Medicine and Dentistry
Acute Myeloid Leukemia
100%
Multiple Myeloma
93%
Patient
77%
Overall Survival
75%
Allogeneic Hematopoietic Stem Cell Transplantation
65%
Cohort Analysis
52%
Cell Transplantation
51%
Transplantation
50%
Adult
48%
Hematopoietic Stem Cell Transplantation
48%
Hematopoietic Cell
45%
Acute Lymphoblastic Leukemia
44%
Aplastic Anemia
31%
Minimal Residual Disease
30%
Stem Cell Therapy
28%
Inpatient
27%
Donor
25%
Survival Rate
25%
Graft Versus Host Reaction
24%
Allogeneic Stem Cell Transplantation
23%
Spontaneous Remission
22%
Progression Free Survival
22%
Hazard Ratio
21%
Therapeutic Procedure
20%
Thymocyte Antibody
20%
Autologous Stem Cell Transplantation
19%
Cumulative Incidence
19%
Conditioning
19%
Low Drug Dose
18%
Melphalan
18%
Disease Free Survival
17%
Precursor
17%
High Risk Population
16%
Survival
16%
Risk Stratification
15%
T Cell
15%
Prognostic Factor
14%
Relapse
14%
B Cell
13%
Acute Myelogenous Leukemia
13%
Graft Versus Host Reaction
13%
Acute Promyelocytic Leukemia
12%
Epstein Barr Virus
12%
COVID-19
12%
Bortezomib
12%
Liver Venoocclusive Disease
12%
Chemotherapy
12%
Acute Graft Versus Host Disease
12%
Diffuse Large B-Cell Lymphoma
12%
Fludarabine
12%
Immunology and Microbiology
Multiple Myeloma
73%
Overall Survival
50%
Myeloid
47%
Hematopoietic Cell
42%
Cell Transplantation
42%
Allogeneic Hematopoietic Stem Cell Transplantation
39%
Graft-Versus-Host Disease
34%
Conditioning
32%
Aplastic Anemia
31%
Hematopoietic Stem Cell Transplantation
27%
Anti-Thymocyte Globulin
25%
Stem Cell Transplantation
23%
Low Drug Dose
18%
Disease Free Survival
17%
Allogeneic Stem Cell Transplantation
17%
Autologous Stem Cell Transplantation
16%
B Cell
16%
Daratumumab
15%
Survival Rate
15%
Progression Free Survival
15%
Dexamethasone
15%
Chronic Graft Versus Host Disease
14%
Acute Graft Versus Host Disease
14%
Blinatumomab
13%
Engraftment
13%
Recurrence Free Survival
12%
Lenalidomide
12%
High Risk Population
11%
Multiple Myeloma
11%
Myeloid-Derived Suppressor Cell
11%
Myeloid
10%
T Cell
9%
Failure Free Survival
9%
Immunocompetent Cell
8%
Overall Survival
8%
Inotuzumab Ozogamicin
8%
Transplant Procedure
8%
Stem Cell
7%
Hemophagocytic Lymphohistiocytosis
7%
Tumor Suppressor Gene
7%
Natural Killer Cell
7%
Precursor
7%
Philadelphia 1 Chromosome
6%
Transplantation
6%
Peripheral Blood Stem Cell Transplantation
6%
Natural Killer T Cell
6%
Hematopoietic Stem Cell Transplantation
6%
Epstein Barr Virus
6%
Recurrence Free Survival
5%
Comorbidity
5%
Pharmacology, Toxicology and Pharmaceutical Science
Multiple Myeloma
75%
Overall Survival
42%
Remission
28%
Acute Myeloid Leukemia
25%
Acute Lymphoblastic Leukemia
22%
Progression Free Survival
22%
Cohort Study
22%
Dexamethasone
21%
Lenalidomide
17%
Melphalan
15%
Graft Versus Host Reaction
14%
Survival Rate
14%
Daratumumab
14%
Aplastic Anemia
12%
Blinatumomab
12%
Bortezomib
11%
Cytarabine
10%
Carfilzomib
10%
Monotherapy
9%
Busulfan
8%
Disease Free Survival
7%
Multiple Myeloma
7%
Promyelocytic Leukemia
7%
Arsenite
7%
Etoposide
7%
Myelodysplastic Syndrome
7%
Case-Control Study
7%
Inotuzumab Ozogamicin
7%
Liver Venoocclusive Disease
7%
Liver Vein Obstruction
7%
Overall Survival
7%
Retrospective Study
7%
Survival
7%
Mortality Rate
7%
Acute Graft Versus Host Disease
6%
Philadelphia 1 Chromosome
6%
Minimal Residual Disease
6%
SARS Coronavirus
6%
Fludarabine
6%
Intestine Flora
6%
Graft Failure
6%
Enalapril Maleate
5%
Leukemia
5%
Acute Myeloid Leukemia
5%
Antibiotic Agent
5%
Venetoclax
5%
Prevalence
5%
Feces microflora
5%
Daratumumab
5%
Deferasirox
5%